Search clinical trials for: BIIB041 (Fampridine-SR)

Total 810 results

Biogen
Acorda Therapeutics

Completed

Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Multiple Sclerosis

Canada
Biogen

Terminated

Fampridine Pregnancy Exposure Registry

Multiple Sclerosis | Pregnancy

France
Acorda Therapeutics

Completed

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
Biogen

Completed

A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis (MOTION - JAPAN)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent Progressive

Japan
Biogen

Completed

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (ENHANCE)

Multiple Sclerosis

United States, Finland, Italy, United Kingdom, Bulgaria, Serbia, Russian Federation, Lithuania, Poland, Czech Republic, Netherlands
Biogen

Completed

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice (LIBERATE)

Multiple Sclerosis

France, Spain, Germany, Netherlands, Argentina, Czechia, Israel, Portugal, United Arab Emirates, Canada, Norway, Lebanon, Ireland
Biogen

Completed

Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis. (MOBILE)

Multiple Sclerosis

Sweden, United Kingdom, Netherlands, Belgium, Canada, Italy
Biogen

Completed

Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

Advanced Solid Tumors

United States
Biogen
Acorda Therapeutics

Completed

A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers

Healthy

Hong Kong, Australia
Biogen

Completed

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

Healthy

United States
Kessler Foundation
National Institute on Disability, Independent Living, and Rehabilitation... and other collaborators

Completed

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

Spinal Cord Injury

United States
Prof. Dominique de Quervain, MD
University Hospital, Basel, Switzerland; Clinical Trial Unit, University Hospital...

Withdrawn

Influence of Fampridine on Working Memory in Healthy Subjects (Fampyr_2020)

Working Memory

Switzerland
Acorda Therapeutics

Completed

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

Muscle Spasticity | Spinal Cord Injury

United States, Canada
Courtney Casserly

Recruiting

Fampridine-SR and Optic Neuritis Recovery (FAMP-ON)

Optic Neuritis

Canada
Prof. Dominique de Quervain, MD
University Hospital, Basel, Switzerland; Clinical Trial Unit, University Hospital...

Completed

Influence of Fampridine on Working Memory in Healthy Young Subjects (FamH)

Working Memory

Switzerland
Acorda Therapeutics

Completed

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

Muscle Spasticity | Spinal Cord Injury

United States, Canada
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Multiple Sclerosis

United States, Canada
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Multiple Sclerosis

United States, Canada
London Health Sciences Centre

Completed

Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?

Cognitive Fatigue

Canada
Prof. Dominique de Quervain, MD
University Hospital, Basel, Switzerland; Clinical Trial Unit, University Hospital...

Active, not recruiting

Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment (FamC)

Working Memory | Post-covid-19

Switzerland
University of Southern Denmark
Biogen; Region of Southern Denmark

Completed

Resistance Training and Amino Pyridine in Multiple Sclerosis (RETRAP)

Multiple Sclerosis

Denmark
Biogen

Completed

Single-Dose Study of a New Formulation of BIIB061

Multiple Sclerosis

United States
Biogen

Completed

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer

United States
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Healthy

United States
Acorda Therapeutics

Completed

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Biogen

Completed

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
University of Southern Denmark
Biogen; Region of Southern Denmark

Completed

FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (FAME)

Multiple Sclerosis

Denmark
Biogen

Recruiting

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis (FUSION)

Relapsing Forms of Multiple Sclerosis

Spain, United States, Italy, Switzerland, Germany, Bulgaria, Czechia, Poland, Puerto Rico, Romania
Biogen

Completed

New Formulation and Food Effect Study of BIIB074

Trigeminal Neuralgia (TN) | Other Neuropathic Pain

United States
Acorda Therapeutics

Completed

Study of Oral Fampridine-SR in Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
Biogen

Completed

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

Healthy Volunteers

United States
Biogen

Completed

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

Breast Cancer

United States
University of Alabama at Birmingham

Not yet recruiting

Effects of Sustained-release Oral Sodium Nitrite on Postoperative Pain and Recovery Following Total Knee Arthroplasty

Pain
G&E Herbal Biotechnology Co., LTD

Completed

Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis (AK)

Actinic Keratosis | Bowen's Disease

Taiwan
Otsuka Pharmaceutical Development & Commercialization...

Completed

Study of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 Sustained Release (SR) in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder

Adult ADHD

United States
NYU Langone Health

Terminated

Stress Reduction Intervention for Women With Ischemic Heart Disease

Ischemic Heart Disease

United States
Biogen

Completed

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

Healthy Volunteer

United States
Biogen

Terminated

Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL

B-Cell Chronic Lymphocytic Leukemia

United States
Biogen

Terminated

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Netherlands, Switzerland
Biogen

Completed

Administration of BIIB028 to Subjects With Solid Tumors

Advanced Solid Tumors

United States
Biogen

Active, not recruiting

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy (DEVOTE)

Muscular Atrophy, Spinal

China, United States, Netherlands, Spain, Korea, Republic of, Taiwan, Australia, Canada, Chile, Saudi Arabia, Poland, Israel, Brazil, Russian Federation, Hungary, Japan, United Kingdom, Italy, Germany, Estonia, Greece, Mexico, Colombia and more
Biogen
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease (REASON)

Parkinson's Disease

United States, Spain, Israel, Canada, Norway, United Kingdom
Biogen

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, Canada, United Kingdom, Ireland, Netherlands, Switzerland
Biogen

Completed

A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants

Healthy Volunteers

United Kingdom
Biogen

Terminated

Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 (RELAY-1 Extend)

Neuropathic Pain From Lumbosacral Radiculopathy

Spain, United Kingdom, Slovakia, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Italy, Latvia, Romania, Serbia, Estonia
Biogen

Completed

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

Alzheimer's Disease

United States
AVAVA, Inc.

Completed

AVAVA SR-1 Wrinkles and BPL Study

Wrinkle | Benign Pigmented Lesion

United States

3

Subscribe